HEALTH● LOWAug 18 · Aug 18, 2026, 3:03 PM
NRx targets 2026 KETAFREE approval and outlines SPARC-TMS trial in 400 patients backed by military funding
Seeking Alpha Tech
NRx aims for KETAFREE approval by 2026 and has outlined a SPARC-TMS trial involving 400 patients. This medical research is supported by military funding.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH29m agoEbola: Nigerian govt says no restrictions on large gatherings for nowPremium TimesHEALTH39m agoWhy measles outbreak in Pennsylvania poses risks beyond US bordersAl Jazeera [en]HEALTH57m agoEbola: APC campaign council accuses Atiku of politicising disease outbreak, says N10bn fund intactPremium TimesHEALTH1h agomRNA cancer vaccine slashes melanoma death or recurrence risk by 42%The Independent World